Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) presented lymphoma data at ASH 2025 highlighting targeted protein degradation and cell therapy advances. Key readouts: golcadomide plus R-CHOP showed a 24-month PFS of 79% with CMR 88% and MRD negativity 90%; golcadomide plus rituximab in FL showed ORR 97% and CRR 78%; BMS-986458 monotherapy showed ORR 65% overall. Long-term Breyanzi results: four-year PFS 52.2% and OS 61.5% in TRANSFORM; TRANSCEND FL 36-month CR 94% and DOR 70%. No new safety signals reported for investigational agents; Breyanzi safety profile reaffirmed.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval of Breyanzi (lisocabtagene maraleucel) on December 5, 2025, as the first and only CAR T therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) after ≥2 prior systemic therapies.
Approval was based on TRANSCEND FL MZL cohort results: ORR 95.5% (n=66), CR 62.1%, median duration of response not reached, and 90.1% of responders in response at 24 months; safety was consistent with prior data.
Terray Therapeutics announced on December 3, 2025 that it achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb (NYSE: BMY). The milestone used Terray’s EMMI platform, which integrates generative AI, high-throughput chemical experimentation, and a rapidly expanding 13B+ target-ligand binding database with an automated lab.
The company said EMMI enables rapid, iterative discovery and optimization of novel small molecules for difficult-to-drug targets by combining advanced hardware, AI models, and structure-activity data to accelerate identification of development candidates for areas with significant unmet medical need.
Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.
The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.
Bristol Myers Squibb (NYSE: BMY) disclosed more than 95 data disclosures, including 27 oral presentations, at ASH 2025 highlighting advances across multiple myeloma, lymphomas and myeloid diseases.
Key clinical updates include durable responses with CELMoD agents: iberdomide (maintenance and combos) showing sustained MRD negativity in newly diagnosed multiple myeloma, golcadomide with continued efficacy at 24 months in aggressive B-cell lymphoma and extended follow-up in R/R FL and DLBCL, and a first-in-class BCL6 ligand-directed degrader showing encouraging activity in R/R NHL.
Long-term liso-cel (Breyanzi) data show sustained benefit at 3–4 years in FL and LBCL; full safety profiles, including CRS and neurologic event rates, were reported.
Bristol Myers Squibb (NYSE: BMY) will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will appear in a fireside chat beginning at 9:00 a.m. ET. Investors and the public can listen live via http://investor.bms.com, and an archived edition will be available after the session.
The company reiterated its mission to discover, develop and deliver innovative medicines. Media and investor contact emails are provided for follow-up.
Bristol Myers Squibb (NYSE: BMY) announced that on November 24, 2025 the European Commission approved Breyanzi (lisocabtagene maraleucel) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior systemic therapies including a BTK inhibitor. Approval covers EU member states and EEA countries Iceland, Norway and Liechtenstein.
Approval is based on TRANSCEND MCL results: overall response rate 82.7%, complete response 71.6%, and 50.8% of patients still in response at 24 months. Safety was consistent with known profile; most CRS and neurologic events occurred early and resolved.
Bristol Myers Squibb (NYSE: BMY) will host a virtual investor event on Thursday, December 11, 2025 following the conclusion of the American Society of Hematology Annual Meeting and Exposition. The webcast begins at 9:00 a.m. ET and will highlight the company’s Hematology development strategy and recent data.
Materials will be available at http://investor.bms.com at the start of the presentation, and a replay will be posted approximately three hours after the event concludes. Company representatives will provide an overview for investors and analysts.
Bristol Myers Squibb (NYSE: BMY) announced accepted amounts and pricing for its previously announced tender offers for multiple series of outstanding notes. Bristol Myers Squibb set the Amended Pool 1 Maximum at approximately $3.99 billion and the Amended Pool 2 Maximum at approximately $3.51 billion. All Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1–4 tendered by the Early Tender Deadline were accepted in full; the company accepted $250,000,000 of 5.900% 2033 Notes on a prorated basis (approx. 50.84% proration).
The Early Settlement Date is November 20, 2025, and accepted Notes will be cancelled and retired.
Bristol Myers Squibb (NYSE: BMY) reported early participation results for its tender offers as of 5:00 p.m. on November 17, 2025.
The company amended Pool 1 and Pool 2 maximums: Pool 1 maximum decreased to accept all Pool 1 Notes validly tendered; Pool 2 maximum increased to accept all Pool 2 Notes with acceptance priority 1–4 and up to $250,000,000 of 5.900% Notes due 2033. The Early Settlement Date is November 20, 2025; Offers expire on December 3, 2025 if not earlier terminated.
Principal amounts tendered by series are listed and Bristol Myers Squibb expects no final settlement or additional acceptances after the Early Tender Deadline.